The Indian healthcare market is bracing for a significant change as more than twenty generic variants of semaglutide, a highly sought-after drug for obesity and diabetes, are set to be introduced in the coming weeks. This development follows the impending patent expiration of the molecule, originally developed by Novo Nordisk, on March 20 in India and other nations. The release of these lower-cost alternatives by domestic pharmaceutical companies is expected to enhance accessibility to treatments that have previously been financially unattainable for many patients.

Current Availability of Semaglutide in India

Currently, semaglutide is marketed in India under three key brands from Novo Nordisk: Rybelsus, an oral tablet; and the injectables Ozempic and Wegovy. Rybelsus became available in 2022, while Ozempic and Wegovy were introduced to the Indian market just last year. Their arrival coincided with the debut of Mounjaro by Eli Lilly, another GLP-1-based drug used for weight management and diabetes treatment, containing the active ingredient tirzepatide. Together, these medications have rapidly gained prominence in the field of metabolic medicine.

Mechanism and Popularity of GLP-1 Therapies

GLP-1 therapies function by imitating gut hormones that play critical roles in appetite regulation, insulin release, and digestion. By binding to receptors that influence pancreatic hormone output and gastrointestinal activity, these drugs effectively manage blood sugar levels while suppressing appetite. This dual function makes them increasingly favored for treating both type 2 diabetes and obesity, conditions that often coexist.

Domestic Manufacturers Prepare for Generic Release

The recent surge in interest for effective weight-loss treatments has drawn the attention of domestic manufacturers. Industry insiders indicate that over a dozen Indian pharmaceutical firms are gearing up to release generic semaglutide products once patent protection wanes. Initial entrants are expected to include companies such as Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, and Zydus Lifesciences. The anticipated competition among these manufacturers is likely to dramatically decrease prices, with estimates suggesting a reduction of about 60 to 70 percent, making the treatment more affordable for Indian patients.

Current Pricing and Future Projections

At present, the cost of semaglutide remains high. A month’s supply of Rybelsus is priced between Rs 6,900 and Rs 9,000, while injectable Ozempic generally costs between Rs 8,800 and Rs 11,000 per month. Wegovy, which is primarily prescribed for weight management, ranges from Rs 11,850 to Rs 26,050 depending on dosage strength. The introduction of generic options may significantly lower these costs over time.

Wide Range of Generic Versions Under Development

Market analysts estimate that nearly 50 versions of generic semaglutide are currently in various stages of development within the pharmaceutical sector. As more manufacturers enter the market and production efforts expand, prices could potentially decrease by as much as 80 to 90 percent when compared to existing branded therapies. This expected decline in prices is likely to enhance accessibility in a country facing rising obesity and diabetes rates.

Anticipated Changes in Treatment Protocols

With the incoming wave of generic semaglutide, specialists believe that treatment protocols for obesity and diabetes in India might undergo significant revisions. According to endocrinologists, the broader availability of this medication could allow healthcare providers to consider GLP-1 therapies earlier in the treatment process, rather than limiting them to patients who have unsuccessfully tried multiple oral medications. The developments indicate a potential turning point in the management of these conditions.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share